Results
Edwards Lifesciences Q1 EPS Beat, Guidance Raised
Edwards Lifesciences reported Q1 adjusted EPS of $0.78, beating consensus $0.73, and revenue $1.65 bn, up 16.7% YoY.
Company lifted FY2026 constant‑currency sales growth outlook to 9‑11% and full‑year
